{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"4","value":"3"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"1","value":"1"},{"groupId":"OG002","lowerLimit":"1","upperLimit":"3","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"Time in months to \\>50-90% reduction in serum IgM from baseline","dispersionType":"Full Range","groups":[{"description":"* Ibrutinib administered orally once daily for 48 cycles\n* Ulocuplumab administered intravenously at 400mg for Cycle 1 on Days 1, 8, 15, and 22. Ulocuplumab administered IV at 800mg for Cycles 2-6 on Days 1 and 15.","id":"OG000","title":"Phase 1 Dose Level 1: Ibrutinib + Ulocuplumab 400mg Cycle 1 and 800mg Cycles 2-6"},{"description":"* Ibrutinib administered orally once daily for 48 cycles\n* Ulocuplumab administered intravenously at 800mg for Cycle 1 on Days 1, 8, 15, and 22. Ulocuplumab administered IV at 1200mg for Cycles 2-6 on Days 1 and 15.","id":"OG001","title":"Phase 1 Dose Level 2: Ibrutinib + Ulocuplumab 800 mg Cycle 1 and 1200mg Cycles 2-6"},{"description":"* Ibrutinib administered orally once daily for 48 cycles\n* Ulocuplumab administered intravenously at 800mg for Cycle 1 on Days 1, 8, 15, and 22. Ulocuplumab administered IV at 1600mg for Cycles 2-6 on Days 1 and 15.","id":"OG002","title":"Phase 1 Dose Level 3: Ibrutinib + Ulocuplumab 800mg Cycle 1 and 1600mg Cycles 2-6"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Response evaluated at each cycle day 1, starting at Cycle 2 Day 1 through Cycle 48","title":"Time to Major Response","type":"SECONDARY","unitOfMeasure":"months"}